Delivering improved management and outcomes in diabetic kidney disease in routine clinical care

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 4, 2007, Pages 172-178

  Hardy, Kevin J ^a,b   Furlong, Niall J ^a   Hulme, Shirley A ^a   O'Brien, Sarah V ^a  

^a Whiston Diabetes Centre   (United Kingdom)

^b WHISTON HOSPITAL   (United Kingdom)

Author keywords

Death; Diabetes mellitus; Dialysis; Doubling of serum creatinine; Microalbuminuria; Nephropathy

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; CREATININE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE COMPARISON; EVIDENCE BASED MEDICINE; FEMALE; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HEALTH SERVICES RESEARCH; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING CESSATION;

EID: 34548501522     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070040101     Document Type: Article

References (21)

1. Gross JL, De Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 2005;28:164-76.
2. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organisation Multinational Study of vascular Disease in Diabetes. Diabetes Care 1996;19:305-12.
3. Diabetes Control and Complications Trial Research Group. The effect of the intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
4. UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus. Lancet 1998, 352:837-53.
5. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
6. UKPDS Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
7. Gaede P, Vedel P, Parving H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
8. Parving HH, Lehnert H, Brochner-Mortenson B et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
9. Lewis EJ, Hunsicker, LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
10. Brenner BM, Cooper ME, Zeeuw D, Keane WF. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
11. Mogensen CE, Cooper ME. Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 2004;21:4-17.
12. ADA (American Diabetes Association). Nephropathy in Diabetes (Position Statement). Diabetes Care 2004;27(suppl 1):S79-S83.
13. National Institute for Clinical Excellence. Management of type 2 diabetes. Renal disease - prevention and early management. Inherited Clinical Guideline F. London, NICE, London: 2005.
14. Renal Association. Treatment of adults and children with renal failure: standards and audit measures, 3rd Edition, 2002. www.renal.org/Standards/ RenalStandards_2002b.pdf
15. Rigalleau MD, Lasseur C, Perlemoine C et al. Estimation of Glomerular Filtration Rate in Diabetic Subjects. Cockcroft Gault or Modification of Diet in Renal Disease study Equation? Diabetes Care 2005;28:838-43.
16. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. MICRO_HOPE Substudy. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet 2000; 355:253-9.
17. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduced rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.
18. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-16.
19. de Zeeuw D, Remuzzi G, Parving HH, Keane WF et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20.
20. Mogensen CE. Microalbuminuria and hypertension with a focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45-66.
21. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: blood pressure independent effect. Circulation 2002;106:672-8.